HSF1A |
Catalog No.GC32437
One-Click Copy Product Info
|
HSF1A is an activator of Heat Shock Transcription Factor 1 (HSF1).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1196723-93-9
Sample solution is provided at 25 µL, 10mM.
HSF1A is an activator of Heat Shock Transcription Factor 1 (HSF1) [1]. HSF1A inhibits the activity of the molecular chaperone TRiC/CCT, thereby activating HSF1 and enhancing cellular resistance to protein misfolding and stress [2-3]. HSF1A is primarily used to treat neurodegenerative diseases [4].
In CD150+CD48-LSK hematopoietic stem cells (HSCs), HSF1A (8μM; 10d) enhances the serial reconstitutive activity of HSCs cultured in vitro [5]. In chinese hamster ovary cells, HSF1A (200µM; 1h) protects cells from pertussis toxin-induced cytotoxicity [6].
In wistar kyoto rats, HSF1A (100mg/kg; ip; 4 weeks) ameliorates doxorubicin-induced heart failure in vivo [7]. In ovalbumininduced allergic asthma mice model, HSF1A (1.3g/kg; ig; 5 weeks) treatment not only reduces inflammation and oxidative stress but also significantly attenuates airway fibrosis [8].
References:
[1]. Neef D W, Jaeger A M, Gomez-Pastor R, et al. A direct regulatory interaction between chaperonin TRiC and stress-responsive transcription factor HSF1[J]. Cell reports, 2014, 9(3): 955-966.
[2]. Neef D W, Turski M L, Thiele D J. Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease[J]. PLoS biology, 2010, 8(1): e1000291.
[3]. Steinemann M, Schlosser A, Jank T, et al. The chaperonin TRiC/CCT is essential for the action of bacterial glycosylating protein toxins like Clostridium difficile toxins A and B[J]. Proceedings of the National Academy of Sciences, 2018, 115(38): 9580-9585.
[4]. Liu A Y, Minetti C A, Remeta D P, et al. HSF1, aging, and neurodegeneration[J]. Cell Biology and Translational Medicine, Volume 18: Tissue Differentiation, Repair in Health and Disease, 2022: 23-49.
[5]. Kruta M, Sunshine M J, Chua B A, et al. Hsf1 promotes hematopoietic stem cell fitness and proteostasis in response to ex vivo culture stress and aging[J]. Cell stem cell, 2021, 28(11): 1950-1965. e6.
[6]. Jia J, Zoeschg M, Barth H, et al. The chaperonin TRiC/CCT inhibitor HSF1A protects cells from intoxication with pertussis toxin[J]. Toxins, 2024, 16(1): 36.
[7]. Huang C Y, Kuo W W, Lo J F, et al. Doxorubicin attenuates CHIP-guarded HSF1 nuclear translocation and protein stability to trigger IGF-IIR-dependent cardiomyocyte death[J]. Cell death & disease, 2016, 7(11): e2455-e2455.
[8]. Liu X, Zhang Y, Wu H, et al. HSF1 in macrophages suppressed the progression of asthma via modulating SIRPα/SHP2—Dectin-1/SYK mediated ROS and inflammatory responses[J]. Scientific Reports, 2025, 15(1): 29741.
| Cell experiment [1]: | |
Cell lines | CD150+CD48-LSK hematopoietic stem cells (HSCs) |
Preparation Method | CD150+CD48-LSK HSCs were sorted from the bone marrow of young adult mice directly into 96-well v-bottom plates at a density of 10 cells/well containing freshly made basic HSC culture medium (Prime-XV Mouse Hematopoietic Cell Medium) with SCF (50ng/ml), TPO (50ng/ml), 2-Mercaptoethanol (50μM) and bovine serum albumin (BSA; 0.1%). When specified, basic HSC medium was supplemented with 17-AAG (5nM) or HSF1A (8μM) in 0.02% DMSO. As a control, basic HSC medium was supplemented with 0.02% DMSO. |
Reaction Conditions | 8μM; 10d |
Applications | HSF1A enhances the serial reconstitutive activity of HSCs cultured in vitro. |
| Animal experiment [2]: | |
Animal models | Wistar Kyoto rats |
Preparation Method | Ten-week-old Wistar Kyoto (WKY) rats were used. Rats were housed at a constant temperature (22℃) with a 12-hour light/dark cycle and provided with food and tap water. The animals were divided into three groups: WKY rats (control group), Doxorubicin (DOX) rats, and DOX rats treated with HSF1A. Each group contained five animals. The DOX group received intraperitoneal injections of DOX (5mg/kg) for 6 consecutive weeks, reaching a cumulative dose of 30mg/kg, which has been shown to be cardiotoxic. HSF1A, a small molecule HSF1 activator, was also administered intraperitoneally (100mg/kg/day). |
Dosage form | 100mg/kg; ip; 4 weeks |
Applications | HSF1A ameliorates doxorubicin-induced heart failure in vivo. |
References: | |
| Cas No. | 1196723-93-9 | SDF | |
| Canonical SMILES | O=S(C1=CC=C(CC)C=C1)(NC2=CC(C3=CC=CS3)=NN2C4=CC=CC=C4)=O | ||
| Formula | C21H19N3O2S2 | M.Wt | 409.52 |
| Solubility | DMSO : ≥ 150 mg/mL (366.28 mM);Water : < 0.1 mg/mL (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4419 mL | 12.2094 mL | 24.4188 mL |
| 5 mM | 488.4 μL | 2.4419 mL | 4.8838 mL |
| 10 mM | 244.2 μL | 1.2209 mL | 2.4419 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 24 reference(s) in Google Scholar.)